Archives of Clinical Ophthalmology

Original Research Open Access

Repeatability of Scheimpflug Corneal Tomography in Patients with Keratoconus and Different Body Mass Indices

James S Lewis , Lize Angelo , Akilesh Gokul , Charles NJ McGhee , Mohammed Ziaei

To evaluate the repeatability of corneal tomographic parameters in keratoconus patients across different body mass index (BMI) categories. This prospective study was conducted at the University of Auckland, New Zealand, from June 2021 to June 2022. A total of 243 eyes from keratoconus patients aged 18-45 years were categorized into normal (BMI ≤24.9; n=55), overweight (BMI 25.0-29.9; n=58), and obese (BMI ≥30.0; n=130) groups. Patients underwent three consecutive scans using the Pentacam AXL.

Arch Clin Ophthalmol, 2025, Volume 4, Issue 1, p1-11 | DOI: 10.33696/Ophthalmology.4.015

Review Article Open Access

Lens Clarity and Visual Fatigue in Children: The Role of Eyewear Hygiene and Healthcare Professionals

Mirela Tushe

Visual fatigue, also known as digital eye strain (DES), has become a growing concern among children due to increased exposure to digital screens, especially after the global shift to remote learning during the COVID-19 pandemic. Although prolonged screen time and poor ergonomics are well-recognized contributors, the influence of eyewear hygiene-specifically lens cleanliness-on visual discomfort is less explored.

Arch Clin Ophthalmol, 2025, Volume 4, Issue 1, p12-16 | DOI: 10.33696/Ophthalmology.4.016

Commentary Open Access

Gabapentin for Ocular Surface Disorders: Bridging Molecular Mechanisms to Therapeutic Innovation 

Caterina Gagliano , Alessandro Avitabile , Dario Rusciano

This commentary critically evaluates Rusciano's (2024) comprehensive review on gabapentin (GBP) as a multifaceted therapy for ocular surface diseases, emphasizing its transition from systemic to topical applications. We highlight the review's synthesis of GBP's polypharmacology—spanning calcium channel modulation, anti-inflammatory effects, and neuroprotection—and its innovative integration with nanotechnology (e.g., nanoceria platforms) to overcome corneal delivery challenges while potentially reducing systemic side effects associated with oral administration.

Arch Clin Ophthalmol, 2025, Volume 4, Issue 1, p17-25 | DOI: 10.33696/Ophthalmology.4.017